

# Ahmed Ba-Ssalamah

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4084507/publications.pdf>

Version: 2024-02-01

74  
papers

2,824  
citations

159585

30  
h-index

182427

51  
g-index

76  
all docs

76  
docs citations

76  
times ranked

3799  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group. <i>European Radiology</i> , 2022, 32, 923-937.	4.5	27
2	A Quantitative Magnetic Resonance Cholangiopancreatography Metric of Intrahepatic Biliary Dilatation Severity Detects High-Risk Primary Sclerosing Cholangitis. <i>Hepatology Communications</i> , 2022, 6, 795-808.	4.3	8
3	Influence of age on gadoxetic acid disodium-induced transient respiratory motion artifacts in pediatric liver MRI. <i>PLoS ONE</i> , 2022, 17, e0264069.	2.5	2
4	Evaluation of a single-breath-hold radial turbo-spin-echo sequence for T2 mapping of the liver at 3T. <i>European Radiology</i> , 2022, 32, 3388-3397.	4.5	5
5	Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLD. <i>Journal of Hepatology</i> , 2022, 77, 1005-1013.	3.7	8
6	Author response to Letter to the Editor: MRI-defined sarcopenia predicts mortality in patients with chronic liver disease. <i>Liver International</i> , 2021, 41, 221-222.	3.9	0
7	Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension. <i>Liver International</i> , 2021, 41, 799-809.	3.9	27
8	Spectrum of liver lesions hyperintense on hepatobiliary phase: an approach by clinical setting. <i>Insights Into Imaging</i> , 2021, 12, 8.	3.4	18
9	Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. <i>European Radiology</i> , 2021, 31, 5615-5628.	4.5	14
10	Circulating microRNAs 34a, 122, and 192 are linked to obesity-associated inflammation and metabolic disease in pediatric patients. <i>International Journal of Obesity</i> , 2021, 45, 1763-1772.	3.4	21
11	Imaging of inflammatory disease of the pancreas. <i>British Journal of Radiology</i> , 2021, 94, 20201214.	2.2	3
12	Modern imaging of cholangitis. <i>British Journal of Radiology</i> , 2021, 94, 20210417.	2.2	7
13	Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging. <i>European Radiology</i> , 2020, 30, 370-382.	4.5	55
14	PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 51-60.	6.4	98
15	Hepatocellular adenomas: Understanding the pathomolecular lexicon, MRI features, terminology, and pitfalls to inform a standardized approach. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 1630-1640.	3.4	20
16	Does the Functional Liver Imaging Score Derived from Gadoxetic Acid-enhanced MRI Predict Outcomes in Chronic Liver Disease?. <i>Radiology</i> , 2020, 294, 98-107.	7.3	51
17	Quantification of liver function using gadoxetic acid-enhanced MRI. <i>Abdominal Radiology</i> , 2020, 45, 3532-3544.	2.1	37
18	MRI-defined sarcopenia predicts mortality in patients with chronic liver disease. <i>Liver International</i> , 2020, 40, 2797-2807.	3.9	27

#	ARTICLE	IF	CITATIONS
19	The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study. <i>European Radiology</i> , 2019, 29, 1048-1058.	4.5	18
20	Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases. <i>European Radiology</i> , 2019, 29, 6600-6610.	4.5	19
21	Objective and subjective comparison of virtual monoenergetic vs. polychromatic images in patients with pancreatic ductal adenocarcinoma. <i>European Radiology</i> , 2019, 29, 3617-3625.	4.5	35
22	A Diagnostic Algorithm That Combines Quantitative 18F-FDG PET Parameters and Contrast-Enhanced CT Improves Posttherapeutic Locoregional Restaging and Prognostication of Survival in Patients With Esophageal Cancer. <i>Clinical Nuclear Medicine</i> , 2019, 44, e13-e21.	1.3	9
23	ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 179-193.	4.4	57
24	The clinical value of secretin-enhanced MRCP in the functional and morphological assessment of pancreatic diseases. <i>British Journal of Radiology</i> , 2018, 91, 20170677.	2.2	19
25	“Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed” mutation rate of the marker higher than expected. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2018, 50, 160-166.	0.7	5
26	Austrian consensus guidelines on imaging requirements prior to hepatic surgery and during follow-up in patients with malignant hepatic lesions. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 665-672.	1.9	4
27	Post-hepatectomy liver failure after major hepatic surgery: not only size matters. <i>European Radiology</i> , 2018, 28, 4748-4756.	4.5	52
28	Imaging of the Stomach and Esophagus Using CT and PET/CT Techniques. <i>Medical Radiology</i> , 2018, , 579-618.	0.1	0
29	Imaging of colorectal cancer – the clue to individualized treatment. <i>Innovative Surgical Sciences</i> , 2018, 3, 3-15.	0.7	14
30	Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoxetic Acid-Enhanced MRI. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-9.	0.8	7
31	Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 446-455.	1.9	41
32	Early response evaluation using CT-perfusion one day after transarterial chemoembolization for HCC predicts treatment response and long-term disease control. <i>European Journal of Radiology</i> , 2017, 90, 73-80.	2.6	22
33	Respiratory motion artifacts during arterial phase imaging with gadoxetic acid: Can the injection protocol minimize this drawback?. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 1107-1114.	3.4	27
34	Differentiation of Intrahepatic Cholangiocellular Carcinoma from Hepatocellular Carcinoma in the Cirrhotic Liver Using Contrast-enhanced MR Imaging. <i>Academic Radiology</i> , 2017, 24, 1491-1500.	2.5	13
35	Effects of Portal Hypertension on Gadoxetic Acid-Enhanced Liver Magnetic Resonance. <i>Investigative Radiology</i> , 2017, 52, 462-469.	6.2	14
36	Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we?. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 646-659.	3.4	54

#	ARTICLE	IF	CITATIONS
37	Cross-Sectional Imaging of the Oesophagus Using CT and PET/Techniques. Medical Radiology, 2017, , 507-529.	0.1	0
38	Prognostic value of volumetric PET parameters in unresectable and metastatic esophageal cancer. European Journal of Radiology, 2016, 85, 540-545.	2.6	24
39	Assessment of Orthotopic Liver Transplant Graft Survival on Gadoteric Acidâ€“Enhanced Magnetic Resonance Imaging Using Qualitative and Quantitative Parameters. Investigative Radiology, 2016, 51, 728-734.	6.2	34
40	The diagnostic efficacy of quantitative liver MR imaging with diffusion-weighted, SWI, and hepato-specific contrast-enhanced sequences in staging liver fibrosisâ€“a multiparametric approach. European Radiology, 2016, 26, 539-546.	4.5	55
41	Cost evaluation of gadoteric acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: Results from the VALUE Trial. European Radiology, 2016, 26, 4121-4130.	4.5	32
42	Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer. European Radiology, 2016, 26, 311-321.	4.5	32
43	Markers of sarcopenia quantified by computed tomography predict adverse long-term outcome in patients with resected oesophageal or gastro-oesophageal junction cancer. European Radiology, 2016, 26, 1359-1367.	4.5	172
44	Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging. European Radiology, 2016, 26, 674-682.	4.5	86
45	Morphologic and Molecular Features of Hepatocellular Adenoma with Gadoteric Acidâ€“enhanced MR Imaging. Radiology, 2015, 277, 104-113.	7.3	95
46	P4 radiology of hepatobiliary diseases with gadoteric acid-enhanced MRI as a biomarker. Expert Review of Gastroenterology and Hepatology, 2014, 8, 147-160.	3.0	11
47	The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 2280-2286.	0.8	48
48	Noninvasive Differentiation of Simple Steatosis and Steatohepatitis by Using Gadoteric Acidâ€“enhanced MR Imaging in Patients with Nonalcoholic Fatty Liver Disease: A Proof-of-Concept Study. Radiology, 2014, 271, 739-747.	7.3	70
49	Susceptibility-weighted MR Imaging in the Grading of Liver Fibrosis: A Feasibility Study. Radiology, 2014, 270, 149-158.	7.3	37
50	Gadoteric acid-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen. European Radiology, 2013, 23, 1978-1985.	4.5	41
51	Texture-based classification of different gastric tumors at contrast-enhanced CT. European Journal of Radiology, 2013, 82, e537-e543.	2.6	100
52	Surgical treatment of GIST â€“ An institutional experience of a high-volume center. International Journal of Surgery, 2013, 11, 801-806.	2.7	15
53	Liver Failure after Major Liver Resection: Risk Assessment by Using Preoperative Gadoteric Acidâ€“enhanced 3-T MR Imaging. Radiology, 2013, 269, 777-786.	7.3	77
54	Liver Fibrosis: Histopathologic and Biochemical Influences on Diagnostic Efficacy of Hepatobiliary Contrast-enhanced MR Imaging in Staging. Radiology, 2013, 269, 460-468.	7.3	80

#	ARTICLE	IF	CITATIONS
55	Cross-Sectional Imaging of the Oesophagus Using CT and PET/Techniques. Medical Radiology, 2012, , 369-390.	0.1	0
56	Liver Transplantation. Investigative Radiology, 2012, 47, 353-358.	6.2	34
57	Confident non-invasive diagnosis of pseudolesions of the liver using diffusion-weighted imaging at 3T MRI. European Journal of Radiology, 2012, 81, 1353-1359.	2.6	16
58	Hepatic steatosis assessment with 1H-spectroscopy and chemical shift imaging at 3.0T before hepatic surgery: Reliable enough for making clinical decisions?. European Journal of Radiology, 2012, 81, 2990-2995.	2.6	15
59	Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI?. European Journal of Radiology, 2011, 79, e1-e6.	2.6	79
60	Barrett's esophagus: treatments of adenocarcinomas I. Annals of the New York Academy of Sciences, 2011, 1232, 248-264.	3.8	4
61	Accuracy of hydro-multidetector row CT in the local T staging of oesophageal cancer compared to postoperative histopathological results. European Radiology, 2011, 21, 2326-2335.	4.5	35
62	Texture-based classification of focal liver lesions on MRI at 3.0 Tesla: A feasibility study in cysts and hemangiomas. Journal of Magnetic Resonance Imaging, 2010, 32, 352-359.	3.4	80
63	MR Imaging of Benign Focal Liver Lesions. Magnetic Resonance Imaging Clinics of North America, 2010, 18, 403-419.	1.1	21
64	Diseases of the Esophagus and Stomach. , 2010, , 22-27.		0
65	Dedicated multi-detector CT of the esophagus: spectrum of diseases. Abdominal Imaging, 2009, 34, 3-18.	2.0	66
66	Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions. European Radiology, 2009, 19, 342-357.	4.5	156
67	Magnetic Resonance Imaging of Liver Malignancies. Topics in Magnetic Resonance Imaging, 2007, 18, 445-455.	1.2	17
68	Characterization of Hepatocellular Tumors. Journal of Computer Assisted Tomography, 2005, 29, 181-190.	0.9	33
69	Dedicated Multidetector CT of the Stomach: Spectrum of Diseases. Radiographics, 2003, 23, 625-644.	3.3	180
70	Effect of Contrast Dose and Field Strength in the Magnetic Resonance Detection of Brain Metastases. Investigative Radiology, 2003, 38, 415-422.	6.2	75
71	Atypical Focal Nodular Hyperplasia of the Liver: Imaging Features of Nonspecific and Liver-Specific MR Contrast Agents. American Journal of Roentgenology, 2002, 179, 1447-1456.	2.2	65
72	Imaging articular cartilage defects in the ankle joint with 3D fat-suppressed echo planar imaging: Comparison with conventional 3D fat-suppressed gradient echo imaging. Journal of Magnetic Resonance Imaging, 2002, 16, 209-216.	3.4	29

#	ARTICLE	IF	CITATIONS
73	Detection of focal hepatic lesions: Comparison of unenhanced and SHU 555 A-enhanced MR imaging versus biphasic helical CTAP. Journal of Magnetic Resonance Imaging, 2000, 11, 665-672.	3.4	71
74	Current Noninvasive MR-Based Imaging Methods in Assessing NAFLD Patients. , 0, , .		0